Last reviewed · How we verify
NCT04139408
Safety and Effectiveness of Disposable Pulmonary Surgical Markers in the Localization of Pulmonary Nodules
NA trial testing Disposable Pulmonary Surgical Marker in Lung Cancer in 76 participants. Completed in 26 January 2021.
24 December 2020
Quick facts
| Lead sponsor | Hangzhou Broncus Medical Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 76 |
| Start date | 22 July 2020 |
| Primary completion | 24 December 2020 |
| Estimated completion | 26 January 2021 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Disposable Pulmonary Surgical Marker
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Hangzhou Broncus Medical Co., Ltd.
Who can join
Adults 18 to 70, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
During the VATS procedure, some pulmonary nodules are relatively small or far away from the pleura, resulting that they are difficult to be accurately located during the procedure. The aim of this study is to evaluate the efficacy and safety of using disposable pulmonary surgical markers to localize pulmonary nodules in subjects prior to the resection of pulmonary nodules by video-assisted thoracoscopic surgery (VATS).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Preoperative pulmonary nodule localization: A comparison of hook wire and Lung-pro-guided surgical markers.
He R, Ming C, Lei Y, Chen W, et al · · 2024 · cited 8× · PMID 38118458 · DOI 10.1111/crj.13726
Verify or expand the search:
- PubMed search for NCT04139408
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Hangzhou Broncus Medical Co., Ltd. trials
Trials by the same sponsor.
- NCT04619472 — Safety and Effectiveness of Radiofrequency Ablation System in the Treatment of Peripheral Lung Tumors · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04139408 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hangzhou Broncus Medical Co., Ltd.
- Last refreshed: 19 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04139408.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing